Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes
SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Giménez as the winner of the CareDx sponsored ISHLT Innovation Challenge Award.
Read the full press release on CareDx.com